Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884863 | 0.70 | SIGMAR1 (0.35) | — | |
| SCHEMBL4936112 | 0.69 | SIGMAR1 (0.39) | SLC6A2ESR1S1PR1MEN1KMT2A | |
| SCHEMBL11224700 | 0.68 | SLC6A2 (0.44) | SLC6A2ESR1S1PR1MAPTPOLB | |
| SCHEMBL7488302 | 0.68 | — | — | |
| SCHEMBL6436039 | 0.67 | SLC6A2 (0.35) | SLC6A2ESR1S1PR1L3MBTL1MEN1 | |
| SCHEMBL11342832 | 0.66 | SLC6A2 (0.46) | SLC6A2ESR1S1PR1MAPTL3MBTL1 | |
| SCHEMBL11342825 | 0.65 | SLC6A2 (0.48) | SLC6A2MAPTL3MBTL1POLB | |
| SCHEMBL39946 | 0.64 | ESR1 (0.44) | ESR1S1PR1MAPTKDM4EMEN1 | |
| SCHEMBL9818045 | 0.64 | ESR1 (0.44) | ESR1S1PR1MAPTKDM4EMEN1 | |
| SCHEMBL11032897 | 0.62 | CHKA (0.46) | ESR1S1PR1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, ADRB2, REN | SLC6A2 289/4885ESR1 2699/4885PTAFR 1012/4885 |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, F12, UTS2R | SLC6A2 331/4885ESR1 1172/4885PTAFR 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.